nach oben

Current Atherosclerosis Reports

Erschienen in:

01.07.2014 | Vascular Biology (RS Rosenson, Section Editor)

CD39: Interface Between Vascular Thrombosis and Inflammation

verfasst von: Yogendra M. Kanthi, Nadia R. Sutton, David J. Pinsky

Erschienen in: Current Atherosclerosis Reports | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Extracellular nucleotides play a critical role in vascular thrombosis and inflammation. Alterations in purinergic extracellular nucleotide concentrations activate pathways that result in platelet degranulation and aggregation, and endothelial and leukocyte activation and recruitment. CD39, the dominant vascular nucleotidase, hydrolyzes ATP and ADP to provide the substrate for generation of the anti-inflammatory and antithrombotic mediator adenosine. The purinergic signaling system, with CD39 at its center, plays an important role in modulating vascular homeostasis and the response to vascular injury, as seen in clinically relevant diseases such as stroke, ischemia–reperfusion injury, and pulmonary hypertension. A growing body of knowledge of the purinergic signaling pathway implicates CD39 as a critical modulator of vascular thrombosis and inflammation. Therapeutic strategies targeting CD39 offer promising opportunities in the management of vascular thromboinflammatory diseases.

Schenk U, Westendorf AM, Radaelli E, Casati A, Ferro M, Fumagalli M, et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels. Sci Signal. 2008;1(39):ra6. doi:10.1126/scisignal.1160583.PubMed

Kukulski F, Levesque SA, Sevigny J. Impact of ectoenzymes on p2 and p1 receptor signaling. Adv Pharmacol. 2011;61:263–99. doi:10.1016/B978-0-12-385526-8.00009-6.PubMedCrossRef

Deaglio S, Robson SC. Ectonucleotidases as regulators of purinergic signaling in thrombosis, inflammation, and immunity. Adv Pharmacol. 2011;61:301–32. doi:10.1016/B978-0-12-385526-8.00010-2.PubMedCrossRef

Bonner F, Borg N, Burghoff S, Schrader J. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS One. 2012;7(4):e34730. doi:10.1371/journal.pone.0034730.PubMedCentralPubMedCrossRef

Maliszewski CR, Delespesse GJ, Schoenborn MA, Armitage RJ, Fanslow WC, Nakajima T, et al. The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization. J Immunol. 1994;153(8):3574–83.PubMed

Pulte ED, Broekman MJ, Olson KE, Drosopoulos JH, Kizer JR, Islam N, et al. CD39/NTPDase-1 activity and expression in normal leukocytes. Thromb Res. 2007;121(3):309–17. doi:10.1016/j.thromres.2007.04.008.PubMedCentralPubMedCrossRef

Behdad A, Sun X, Khalpey Z, Enjyoji K, Wink M, Wu Y, et al. Vascular smooth muscle cell expression of ectonucleotidase CD39 (ENTPD1) is required for neointimal formation in mice. Purinergic Signal. 2009;5(3):335–42. doi:10.1007/s11302-009-9158-y.PubMedCentralPubMedCrossRef

Smith TM, Kirley TL. Cloning, sequencing, and expression of a human brain ecto-apyrase related to both the ecto-ATPases and CD39 ecto-apyrases1. Biochim Biophys Acta. 1998;1386(1):65–78.PubMedCrossRef

Koziak K, Kaczmarek E, Kittel A, Sevigny J, Blusztajn JK, Schulte Am Esch 2nd J, et al. Palmitoylation targets CD39/endothelial ATP diphosphohydrolase to caveolae. J Biol Chem. 2000;275(3):2057–62.PubMedCrossRef

10.••

Baek AE, Kanthi Y, Sutton NR, Liao H, Pinsky DJ. Regulation of ecto-apyrase CD39 (ENTPD1) expression by phosphodiesterase III (PDE3). FASEB J. 2013;27(11):4419–28. doi:10.1096/fj.13-234625. This is an important study demonstrating pharmacologic modulation of CD39 expression with existing drugs approved by the US Food and Drug Administration. Use of the PDE3 inhibitor family of pharmaceuticals represents a novel approach to harness CD39 expression.PubMedCentralPubMedCrossRef

11.

Papanikolaou A, Papafotika A, Murphy C, Papamarcaki T, Tsolas O, Drab M, et al. Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39. J Biol Chem. 2005;280(28):26406–14. doi:10.1074/jbc.M413927200.PubMedCrossRef

12.

Strohmeier GR, Lencer WI, Patapoff TW, Thompson LF, Carlson SL, Moe SJ, et al. Surface expression, polarization, and functional significance of CD73 in human intestinal epithelia. J Clin Invest. 1997;99(11):2588–601. doi:10.1172/JCI119447.PubMedCentralPubMedCrossRef

13.

Liao H, Hyman MC, Baek AE, Fukase K, Pinsky DJ. cAMP/CREB-mediated transcriptional regulation of ectonucleoside triphosphate diphosphohydrolase 1 (CD39) expression. J Biol Chem. 2010;285(19):14791–805. doi:10.1074/jbc.M110.116905.PubMedCentralPubMedCrossRef

14.

Pluskota E, Ma Y, Bledzka KM, Bialkowska K, Soloviev DA, Szpak D, et al. Kindlin-2 regulates hemostasis by controlling endothelial cell-surface expression of ADP/AMP catabolic enzymes via a clathrin-dependent mechanism. Blood. 2013;122(14):2491–9. doi:10.1182/blood-2013-04-497669.PubMedCentralPubMedCrossRef

15.••

Chalmin F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity. 2012;36(3):362–73. doi:10.1016/j.immuni.2011.12.019. This is an important study that implicates CD39 in the mechanism of immune modulation by T helper 17 cells. It further identifies direct and indirect transcriptional signals that regulate CD39 expression under cellular stress.PubMedCrossRef

16.

Hot A, Lavocat F, Lenief V, Miossec P. Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Ann Rheum Dis. 2013;72(5):754–60. doi:10.1136/annrheumdis-2012-201887.PubMedCrossRef

17.

Robson SC, Kaczmarek E, Siegel JB, Candinas D, Koziak K, Millan M, et al. Loss of ATP diphosphohydrolase activity with endothelial cell activation. J Exp Med. 1997;185(1):153–63.PubMedCentralPubMedCrossRef

18.

Eltzschig HK, Kohler D, Eckle T, Kong T, Robson SC, Colgan SP. Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood. 2009;113(1):224–32. doi:10.1182/blood-2008-06-165746.PubMedCentralPubMedCrossRef

19.

Ogawa S, Clauss M, Kuwabara K, Shreeniwas R, Butura C, Koga S, et al. Hypoxia induces endothelial cell synthesis of membrane-associated proteins. Proc Natl Acad Sci U S A. 1991;88(21):9897–901.PubMedCentralPubMedCrossRef

20.

Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood. 2005;105(2):659–69. doi:10.1182/blood-2004-07-2958.PubMedCrossRef

21.

Banz Y, Beldi G, Wu Y, Atkinson B, Usheva A, Robson SC. CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation. Br J Haematol. 2008;142(4):627–37. doi:10.1111/j.1365-2141.2008.07230.x.PubMedCentralPubMedCrossRef

22.•

Visovatti SH, Hyman MC, Bouis D, Neubig R, McLaughlin VV, Pinsky DJ. Increased CD39 nucleotidase activity on microparticles from patients with idiopathic pulmonary arterial hypertension. PLoS One. 2012;7(7):e40829. doi:10.1371/journal.pone.0040829. This is an important study that demonstrates a potential role for CD39 in pulmonary arterial hypertension, a devastating disease with poor prognosis and limited therapeutics.PubMedCentralPubMedCrossRef

23.

Hyman MC, Petrovic-Djergovic D, Visovatti SH, Liao H, Yanamadala S, Bouis D, et al. Self-regulation of inflammatory cell trafficking in mice by the leukocyte surface apyrase CD39. J Clin Invest. 2009;119(5):1136–49. doi:10.1172/JCI36433.PubMedCentralPubMedCrossRef

24.

Enjyoji K, Sevigny J, Lin Y, Frenette PS, Christie PD, Esch 2nd JS, et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999;5(9):1010–7. doi:10.1038/12447.PubMedCrossRef

25.

Huttinger ZM, Milks MW, Nickoli MS, Aurand WL, Long LC, Wheeler DG, et al. Ectonucleotide triphosphate diphosphohydrolase-1 (CD39) mediates resistance to occlusive arterial thrombus formation after vascular injury in mice. Am J Pathol. 2012;181(1):322–33. doi:10.1016/j.ajpath.2012.03.024.PubMedCentralPubMedCrossRef

26.

Pinsky DJ, Broekman MJ, Peschon JJ, Stocking KL, Fujita T, Ramasamy R, et al. Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain. J Clin Invest. 2002;109(8):1031–40. doi:10.1172/JCI10649.PubMedCentralPubMedCrossRef

27.

Wheeler DG, Joseph ME, Mahamud SD, Aurand WL, Mohler PJ, Pompili VJ, et al. Transgenic swine: expression of human CD39 protects against myocardial injury. J Mol Cell Cardiol. 2012;52(5):958–61. doi:10.1016/j.yjmcc.2012.01.002.PubMedCentralPubMedCrossRef

28.

Cai M, Huttinger ZM, He H, Zhang W, Li F, Goodman LA, et al. Transgenic over expression of ectonucleotide triphosphate diphosphohydrolase-1 protects against murine myocardial ischemic injury. J Mol Cell Cardiol. 2011;51(6):927–35. doi:10.1016/j.yjmcc.2011.09.003.PubMedCentralPubMedCrossRef

29.

Dwyer KM, Robson SC, Nandurkar HH, Campbell DJ, Gock H, Murray-Segal LJ, et al. Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest. 2004;113(10):1440–6. doi:10.1172/JCI19560.PubMedCentralPubMedCrossRef

30.

McRae JL, Russell PA, Chia JS, Dwyer KM. Overexpression of CD39 protects in a mouse model of preeclampsia. Nephrology. 2013;18(5):351–5. doi:10.1111/nep.12058.PubMedCrossRef

31.

Crikis S, Lu B, Murray-Segal LM, Selan C, Robson SC, D’Apice AJ, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant. 2010;10(12):2586–95. doi:10.1111/j.1600-6143.2010.03257.x.PubMedCrossRef

32.

Hatakeyama K, Hao H, Imamura T, Ishikawa T, Shibata Y, Fujimura Y, et al. Relation of CD39 to plaque instability and thrombus formation in directional atherectomy specimens from patients with stable and unstable angina pectoris. Am J Cardiol. 2005;95(5):632–5. doi:10.1016/j.amjcard.2004.11.012.PubMedCrossRef

33.

Kaneider NC, Egger P, Dunzendorfer S, Noris P, Balduini CL, Gritti D, et al. Reversal of thrombin-induced deactivation of CD39/ATPDase in endothelial cells by HMG-CoA reductase inhibition: effects on Rho-GTPase and adenosine nucleotide metabolism. Arterioscler Thromb Vasc Biol. 2002;22(6):894–900.PubMedCrossRef

34.

Kohler D, Eckle T, Faigle M, Grenz A, Mittelbronn M, Laucher S, et al. CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation. 2007;116(16):1784–94. doi:10.1161/CIRCULATIONAHA.107.690180.PubMedCrossRef

35.

Yoshida O, Kimura S, Jackson EK, Robson SC, Geller DA, Murase N, et al. CD39 expression by hepatic myeloid dendritic cells attenuates inflammation in liver transplant ischemia-reperfusion injury in mice. Hepatology. 2013;58(6):2163–75. doi:10.1002/hep.26593.PubMedCrossRef

36.

Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314(5806):1792–5. doi:10.1126/science.1132559.PubMedCrossRef

37.

Eltzschig HK, Thompson LF, Karhausen J, Cotta RJ, Ibla JC, Robson SC, et al. Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood. 2004;104(13):3986–92.PubMedCrossRef

38.

Reutershan J, Vollmer I, Stark S, Wagner R, Ngamsri KC, Eltzschig HK. Adenosine and inflammation: CD39 and CD73 are critical mediators in LPS-induced PMN trafficking into the lungs. FASEB J. 2009;23(2):473–82. doi:10.1096/fj.08-119701.PubMedCrossRef

39.

Corriden R, Chen Y, Inoue Y, Beldi G, Robson SC, Insel PA, et al. Ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPDase1/CD39) regulates neutrophil chemotaxis by hydrolyzing released ATP to adenosine. J Biol Chem. 2008;283(42):28480–6. doi:10.1074/jbc.M800039200.PubMedCentralPubMedCrossRef

40.

Kukulski F, Bahrami F, Ben Yebdri F, Lecka J, Martin-Satue M, Levesque SA, et al. NTPDase1 controls IL-8 production by human neutrophils. J Immunol. 2011;187(2):644–53. doi:10.4049/jimmunol.1002680.PubMedCrossRef

41.

Shah D, Romero F, Stafstrom W, Duong M, Summer R. Extracellular ATP mediates the late phase of neutrophil recruitment to the lung in murine models of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2014;306(2):L152–61. doi:10.1152/ajplung.00229.2013.PubMedCrossRef

42.

Zanin RF, Braganhol E, Bergamin LS, Campesato LF, Filho AZ, Moreira JC, et al. Differential macrophage activation alters the expression profile of NTPDase and ecto-5′-nucleotidase. PLoS One. 2012;7(2):e31205. doi:10.1371/journal.pone.0031205.PubMedCentralPubMedCrossRef

43.

Csoka B, Selmeczy Z, Koscso B, Nemeth ZH, Pacher P, Murray PJ, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J. 2012;26(1):376–86. doi:10.1096/fj.11-190934.PubMedCentralPubMedCrossRef

44.

Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. The sepsis seesaw: tilting toward immunosuppression. Nat Med. 2009;15(5):496–7. doi:10.1038/nm0509-496.PubMedCentralPubMedCrossRef

45.

Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, Mosser DM. TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood. 2013;122(11):1935–45. doi:10.1182/blood-2013-04-496216.PubMedCentralPubMedCrossRef

46.

Levesque SA, Kukulski F, Enjyoji K, Robson SC, Sevigny J. NTPDase1 governs P2X7-dependent functions in murine macrophages. Eur J Immunol. 2010;40(5):1473–85. doi:10.1002/eji.200939741.PubMedCentralPubMedCrossRef

47.

Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225–32. doi:10.1182/blood-2006-12-064527.PubMedCrossRef

48.

Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257–65. doi:10.1084/jem.20062512.PubMedCentralPubMedCrossRef

49.

Dwyer KM, Hanidziar D, Putheti P, Hill PA, Pommey S, McRae JL, et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant. 2010;10(11):2410–20. doi:10.1111/j.1600-6143.2010.03291.x.PubMedCentralPubMedCrossRef

50.

Zhou Q, Yan J, Putheti P, Wu Y, Sun X, Toxavidis V, et al. Isolated CD39 expression on CD4+ T cells denotes both regulatory and memory populations. Am J Transplant. 2009;9(10):2303–11. doi:10.1111/j.1600-6143.2009.02777.x.PubMedCentralPubMedCrossRef

51.

Moncrieffe H, Nistala K, Kamhieh Y, Evans J, Eddaoudi A, Eaton S, et al. High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population. J Immunol. 2010;185(1):134–43. doi:10.4049/jimmunol.0803474.PubMedCentralPubMedCrossRef

52.

Thiolat A, Semerano L, Pers YM, Biton J, Lemeiter D, Portales P, et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 2014;66(2):273–83. doi:10.1002/art.38246.PubMedCrossRef

53.

Kansas GS, Wood GS, Tedder TF. Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes. J Immunol. 1991;146(7):2235–44.PubMed

54.

la Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol. 2001;166(3):1611–7.PubMedCrossRef

55.

Idzko M, Dichmann S, Ferrari D, Di Virgilio F, la Sala A, Girolomoni G, et al. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood. 2002;100(3):925–32.PubMedCrossRef

56.

Mizumoto N, Kumamoto T, Robson SC, Sevigny J, Matsue H, Enjyoji K, et al. CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med. 2002;8(4):358–65. doi:10.1038/nm0402-358.PubMedCrossRef

Titel: CD39: Interface Between Vascular Thrombosis and Inflammation
verfasst von: Yogendra M. Kanthi
Nadia R. Sutton
David J. Pinsky
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Current Atherosclerosis Reports / Ausgabe 7/2014
Print ISSN: 1523-3804
Elektronische ISSN: 1534-6242
DOI: https://doi.org/10.1007/s11883-014-0425-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2014

Copeptin—Marker of Acute Myocardial Infarction

Sitosterolemia: Diagnosis, Investigation, and Management

Primary Prevention of Cardiovascular Disease with Statins in the Elderly

Stable Angina Pectoris

Update on Primary Hypobetalipoproteinemia